Cargando…
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer. PATIENTS AND METHODS: This open-label, nonrandomized, dose-escalation...
Autores principales: | Fu, Siqing, Corr, Bradley R., Culm-Merdek, Kerry, Mockbee, Colleen, Youssoufian, Hagop, Stagg, Robert, Naumann, R. Wendel, Wenham, Robert M., Rosengarten, Rafael D., Benjamin, Laura, Hamilton, Erika Paige, Moore, Kathleen N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362870/ https://www.ncbi.nlm.nih.gov/pubmed/35439029 http://dx.doi.org/10.1200/JCO.21.01801 |
Ejemplares similares
-
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019) -
Enhancement of human plasma glucosylceramide assay sensitivity using delipidized plasma
por: Zheng, Kefei, et al.
Publicado: (2016) -
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
por: Hubbard, Joleen M., et al.
Publicado: (2022) -
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016) -
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)